Subgroup analysis confirms efficacy of Omni MIGS device in Hispanic patients
Click Here to Manage Email Alerts
A subset of Hispanic patients within the larger GEMINI study confirmed the good outcomes of combined canaloplasty and trabeculotomy performed with the Omni surgical system at the time of cataract surgery.
The Omni surgical system (Sight Sciences) is a single-use, handheld device that allows performing microcatheterization and viscodilation of Schlemm’s canal followed by trabeculotomy through a single clear corneal microincision. Through this double MIGS procedure, all three sources of outflow resistance — trabecular meshwork, Schlemm’s canal and collector channels — are treated.
GEMINI was a prospective, multicenter study that included 149 patients with mild to moderate open-angle glaucoma at 15 centers in the U.S. After treatment, a mean IOP reduction of 35%, from 23.8 mm Hg to 15.6 mm Hg, without medications was achieved at 12 months, with 76% of eyes achieving IOP values between 6 mm Hg and 18 mm Hg. Medication use was reduced from a mean of 1.8 before treatment to 0.4 after treatment, and 80% of eyes were medication free. IOP fluctuation was reduced by 36% compared with preoperative measurements.
In the Hispanic population subset, IOP lowering was also 35%, and 85% of the patients achieved a reduction of 20% or more. Medications were reduced from 0.43 to 0.15, and 87% of patients required no medications.
“We now have 12 months of prospective, multicenter data showing 360° canaloplasty and 180° trabeculotomy performed with the Omni surgical system at the time of cataract surgery significantly reduced unmedicated mean diurnal IOP and medication use at 12 months postoperatively,” Mark J. Gallardo, MD, said in a press release from Sight Sciences. “This conclusion was also observed in the Hispanic population, where there’s increased prevalence of glaucoma with a higher proportion who are undiagnosed.”
Reference:
Sight Sciences’ Omni surgical system reduces IOP, daily fluctuations in IOP and medication use, as shown in newly published 12-month clinical data. https://www.sightsciences.com/us/gemini-12-month-outcomes/. Published May 31, 2022. Accessed May 31, 2022.
Collapse
Read more about
Click Here to Manage Email Alerts